While market jitters have kept some IPO candidates on the sidelines, biotechs continue to tap the public market, with two more on the calendar for the week ahead.RNA interference biotech City ...

Two biotechs priced IPOs this past week and more joined the pipeline, along with a billion-dollar data center developer, an emerging markets fintech, and a dental treatment company.Autoimmune biotech ...

Patriot Mobile, a wireless communications company focused on Christian-conservative organizations, filed on Friday with the ...

Aspen Neuroscience, a Phase 1/2a biotech developing stem cell therapies for Parkinson’s disease, filed on Friday with the SEC ...

OPay, a digital bank and fintech platform in Nigeria and other emerging markets, filed on Friday with the SEC for an initial public offering we estimate could raise up to $500 million.

Vardis Holding, which sells proprietary non-invasive restorative treatments for early-stage cavities, filed on Friday with the SEC for an initial public offering that we estimate could raise $200 ...

City Therapeutics, a Phase 1 biotech developing RNA interference therapies for thromboembolic diseases, announced terms for ...

Retension Pharmaceuticals, a Phase 2b biotech developing an in-licensed treatment for hypertension, raised $45 million by ...

Amaero, a producer of titanium and refractory metal powders for defense and aerospace 3D printing, revived its US IPO plans on Thursday with a new SEC filing disclosing a lower proposed share offering ...

Calm Seas Acquisition, a blank check company targeting the energy and shipping industries, lowered the proposed deal size for ...

Our clients are focused on catalyzing growth and creating value. Not scouring the web for IPO data. Get the information you need in minutes, not hours. With IPO Pro, you have the entire US IPO market ...

Iambic Therapeutics, a Phase 1 biotech using its AI platform to develop small molecule cancer therapies, announced terms for ...